Graves' disease and hyperthyroidism: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• PD-1 0
• PD-L1 0
• SGLT2 0
• TP53 0
• BRAF 0
• CTLA-4 0
• EGFR 0
• FTO 0
• GLP-1 0
• PCSK9 0
• RAS 0
• TERT 0

521 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-CSA

  Innovating Thyroid Health with Genomics and Predictive Algorithms through Collaborative Excellence (InnoThyroGen)

  Sveuciliste U Splitu Medicinski Fakultet· Split, Horvátország· EU contribution 4 937 275 EUR· until 2028. dec.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

1 of 1 running projects, newest first. Listed amounts together: 4,9 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Felfüggesztve

  Personalized Treatment in Thyroid Disorders

  NCT03517579· Johns Hopkins University· Frissítve: 2026. okt. 22.

  “Funding issues”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease

  NCT05678374· Vastra Gotaland Region· Frissítve: 2026. szept. 14.

  “We had initially planned to include 60 participants per group. However, due to substantial difficulties with participant recruitment, we decided to close the study after enrolling 39, 15, and 40 participants in the respective groups.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  The Sequestration of Holistic Stress Management Techniques for Adults

  NCT06098755· Goddess Zena I. Jones· Frissítve: 2026. febr. 4.

  “No Participants Enrolled”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery

  NCT05774535· Istituto Auxologico Italiano· Frissítve: 2025. okt. 2.

  “No enrollment”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Radiofrequency Ablation Versus I-131 for Solitary Autonomous Thyroid Nodules

  NCT05142904· Rijnstate Hospital· Frissítve: 2025. júl. 17.

  “Switched from RCT to observational prospective cohort due to termination of subsidy (delay due to insufficient inclusion-rate). Follow-up of RCT-arm will be completed. Patients can still be included in a observational cohort.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Phase 2 Study to Assess Efficacy & Safety of WP1302 Prevent Relapse of MMI w/Draw in Subj. w/ Graves' dz

  NCT06240455· Worg Biotherapeutics Inc.· Frissítve: 2025. máj. 8.

  “Not feasible to recruit suitable subjects”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Efficacy of Methimazole Dosing Algorithm

  NCT05964452· Cook County Health· Frissítve: 2024. dec. 27.

  “Unable to reach recruiting goals”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old

  NCT07722546· Biogen· Forrás

• Hydroxychloroquine in Mild Graves' Orbitopathy

  NCT05126147· National Taiwan University Hospital· Forrás

• A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease

  NCT06984627· Sanofi· Forrás

• Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease

  NCT07369063· Northwell Health· Forrás

• Thyroid-Stimulating Hormone Receptor (TSHR) Blockade With REGN24493 in Adult Participants With Graves' Disease (GD)

  NCT07861152· Regeneron Pharmaceuticals· Forrás

• A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

  NCT06401044· Amgen· Forrás

• An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease

  NCT07438405· Amgen· Forrás

• A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease

  NCT06248619· Amgen· Forrás

• Rubus Sanctus (Wild Blackberry) Root Extract as a Dietary Supplement for Graves' Disease

  NCT07164079· Betul Uner· Forrás

• In Vivo CAR-T for Refractory Graves' Disease

  NCT07333677· Shanghai Zhongshan Hospital· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 3
• Organoids 1
• Mendelian Randomization Analysis 29
• CRISPR-Cas Systems 1
• Gene Expression Profiling 14
• Sequence Analysis, RNA 2
• Proteomics 3
• Metabolomics 9
• Mass Spectrometry 5
• Flow Cytometry 3
• Immunohistochemistry 7
• Positron-Emission Tomography 2
• Magnetic Resonance Imaging 49
• Machine Learning 15
• Deep Learning 5
• Cohort Studies 69
• Genome-Wide Association Study 25

• Wernicke's encephalopathy secondary to hyperemesis gravidarum in pregnancy.

  Indian J Pharmacol, 2026. nov.

• Quantitative evaluation of synthetic MRI for assessing disease activity in thyroid eye disease.

  Eur Radiol Exp, 2026. szept.

• Adjunctive Orbital Radiation Therapy with Teprotumumab in Recalcitrant Thyroid Eye Disease: A Case Report.

  Ophthalmic Plast Reconstr Surg, 2026. szept.

• Thyroid-stimulating hormone-secreting pituitary neuroendocrine tumor (TSH-PitNet) diagnosed during pregnancy and treated with a somatostatin analog.

  Taiwan J Obstet Gynecol, 2026. szept.

• Integrated 18F-NOTA-FAPI-04 PET/MRI for quantitative assessment of disease activity in thyroid-associated ophthalmopathy.

  Eur J Nucl Med Mol Imaging, 2026. aug.

• Selective extraocular muscle regression following tocilizumab in active thyroid associated ophthalmopathy: a 3D MRI-based retrospective study.

  Front Endocrinol (Lausanne), 2026. aug.

• Case Report: Teprotumumab treatment in an HIV-infected patient with refractory thyroid eye disease: clinical and quantitative MRI evidence.

  Front Immunol, 2026. aug.

• Reduction in extraocular muscle and orbital fat volumes after teprotumumab treatment in Japanese patients with thyroid eye disease: an exploratory magnetic resonance imaging analysis from the OPTIC-J trial.

  Jpn J Ophthalmol, 2026. aug.

• Graves' disease-related reversible intracranial arteriopathy presenting with ischemic stroke: A case report and literature review.

  Medicine (Baltimore), 2026. júl.

• [Expert consensus on orbital MRI examination and diagnostic evaluation in thyroid eye disease (2026 edition)].

  Zhonghua Yi Xue Za Zhi, 2026. júl.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.